The US Meals and Drug Administration could finalize authorization for the primary COVID-19 vaccine later immediately, Friday, which might speed up an already breakneck regulatory tempo within the wake of intense strain and threats from the Trump Administration.
In accordance with a number of studies, the FDA was anticipating to finalize the Emergency Use Authorization for the two-dose Pfizer/BioNTech COVID-19 vaccine early Saturday. That closing log off would land lower than 48 hours after the company’s unbiased advisory committee endorsed granting the EUA in a vote late Thursday of 17 to 4, with one abstention.
Earlier this week, the FDA launched a briefing of its personal evaluate of the Pfizer/BioNTech mRNA vaccine, discovering it “extremely efficient” and with a “favorable security profile.”
Learn 9 remaining paragraphs | Feedback